Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
Information source: University of Leeds
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension; Left Ventricular Hypertrophy
Intervention: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD (Drug); Valsartan 160mg OD; Moxonidine 400mcg OD (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Leeds Official(s) and/or principal investigator(s):
John P Greenwood, MBChB, PhD, MRCP, Principal Investigator, Affiliation: Leeds University
Summary
Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the
likelihood of complications and death. The high blood pressure explains some but not all of
this increase in heart size. This study will investigate the other causes, and will measure
the heart muscle 'thickness' very accurately using the latest and most accurate technique
called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening
remains to be determined. We hope to be able to show that by specifically targeting the cause
of heart muscle thickening we can reduce its occurrence more effectively than by other
standard means of blood pressure treatment
Clinical Details
Official title: Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Primary outcome: The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups.
Eligibility
Minimum age: 25 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Recently diagnosed essential hypertension (within 6 months).
- Age 25 to 80 years; Weight < 100kg.
- Sinus rhythm without significant ventricular or atrial ectopy.
Exclusion Criteria:
- Current angiotensin II receptor antagonist or ACE Inhibitor treatment.
- Contra-indication to any of the protocol anti-hypertensive agents.
- Angina requiring treatment with a Beta blocker or calcium antagonist
- Any disease affecting the autonomic nervous system e. g. congestive cardiac failure,
diabetes, neurological disease, malignancy, pregnancy.
- Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants,
intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes
etc).
Locations and Contacts
Leeds Teaching Hospital NHS Trust, Leeds, Wesst Yorkshire LS1 3EX, United Kingdom
Additional Information
Cardiac MRI Research Group - Leeds, UK
Starting date: September 2003
Ending date: April 2004
Last updated: August 21, 2007
|
